Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Current Treatment Options in Oncology
Published in: Current Treatment Options in Oncology 3/2013

01-09-2013 | Sarcoma (SH Okuno, Section Editor)

Role of Epigenetic Modulation for the Treatment of Sarcoma

Authors: Gregory M. Cote, MD, PhD, Edwin Choy, MD, PhD

Published in: Current Treatment Options in Oncology | Issue 3/2013

Login to get access

Opinion statement

Sarcoma is a disease that includes many different subtypes that can present with a wide range of differing clinical findings, prognosis, and treatment options. For certain subsets (e.g., Ewing sarcoma, osteosarcoma, rhabdomyosarcoma, gastrointestinal stromal tumor [GIST]), extensive clinical trials have delineated effective treatment regimens often involving combination therapy, including surgery, radiation, systemic chemotherapy, and small molecular inhibitors of tyrosine kinases (as in the case of GIST). For nearly all patients with sarcoma who have relapsed or developed metastasis, the therapeutic benefit of chemotherapy has reached a plateau and as such new treatment approaches are needed to move this field forward. We recommend that all patients have the opportunity to participate in clinical trials where available. Recently, in our clinic we have started to increase our use of molecular testing and DNA sequencing studies to help identify potential treatment options for patients. One area of evolving basic and clinical research in sarcomas is the field of epigenetic therapeutics. The enclosed article reviews the basics of epigenetics and highlights some completed and ongoing clinical trials of epigenetic treatments in sarcoma. We anticipate in the future that diagnostic platforms will be developed to help clinicians determine if an epigenetic therapy could be effective for an individual patient with sarcoma.
Literature
1.
2.
Clark MA, Fisher C, Judson I, Thomas JM. Soft-tissue sarcomas in adults. N Engl J Med. 2005;353(7):701–11.PubMedCrossRef
3.
O'Sullivan B, Davis AM, Turcotte R, et al. Preoperative versus postoperative radiotherapy in soft-tissue sarcoma of the limbs: a randomised trial. Lancet. 2002;359(9325):2235–41.PubMedCrossRef
4.•
Woll PJ, Reichardt P, Le Cesne A, et al. Adjuvant chemotherapy with doxorubicin, ifosfamide, and lenograstim for resected soft-tissue sarcoma (EORTC 62931): a multicentre randomised controlled trial. Lancet Oncol. 2012;13(10):1045–54. This is the largest study of modern adjuvant chemotherapy. There was no difference in PFS or OS. This highlights the need for novel therapies to treat this disease. PubMedCrossRef
5.
Pervaiz N, Colterjohn N, Farrokhyar F, Tozer R, Figueredo A, Ghert M. A systematic meta-analysis of randomized controlled trials of adjuvant chemotherapy for localized resectable soft-tissue sarcoma. Cancer. 2008;113(3):573–81.PubMedCrossRef
6.
Italiano A, Mathoulin-Pelissier S, Cesne AL, et al. Trends in survival for patients with metastatic soft-tissue sarcoma. Cancer. 2011;117(5):1049–54.PubMedCrossRef
7.
Karavasilis V, Seddon BM, Ashley S, Al-Muderis O, Fisher C, Judson I. Significant clinical benefit of first-line palliative chemotherapy in advanced soft-tissue sarcoma: retrospective analysis and identification of prognostic factors in 488 patients. Cancer. 2008;112(7):1585–91.PubMedCrossRef
8.
Grier HE, Krailo MD, Tarbell NJ, et al. Addition of ifosfamide and etoposide to standard chemotherapy for Ewing's sarcoma and primitive neuroectodermal tumor of bone. N Engl J Med. 2003;348(8):694–701.PubMedCrossRef
9.
Goorin AM, Schwartzentruber DJ, Devidas M, et al. Presurgical chemotherapy compared with immediate surgery and adjuvant chemotherapy for nonmetastatic osteosarcoma: Pediatric Oncology Group Study POG-8651. J Clin Oncol. 2003;21(8):1574–80.PubMedCrossRef
10.
11.
Berger SL, Kouzarides T, Shiekhattar R, Shilatifard A. An operational definition of epigenetics. Genes Dev. 2009;23(7):781–3.PubMedCrossRef
12.
Hassler MR, Egger G. Epigenomics of cancer - emerging new concepts. Biochimie. 2012;94(1):2219–30.PubMedCrossRef
13.
Jones PA, Baylin SB. The epigenomics of cancer. Cell. 2007;128(4):683–92.
14.•
Wilson BG, Roberts CW. SWI/SNF nucleosome remodellers and cancer. Nat Rev Cancer 2011;11:481–92. There is now an emerging understanding of SWI/SNF nucleosome remodeling in malignancy. This review nicely summarizes this disease model and compiles known data on SWI/SNF subunit mutations in cancer.PubMedCrossRef
15.
Siddiqi S, Mills J, Matushansky I. Epigenetic remodeling of chromatin architecture: exploring tumor differentiation therapies in mesenchymal stem cells and sarcomas. Curr Stem Cell Res Ther;5(1):63-73.
16.
Herman JG, Baylin SB. Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med 2003;349:2042–54.
17.
Costello JF, Fruhwald MC, Smiraglia DJ, et al. Aberrant CpG-island methylation has non-random and tumour-type-specific patterns. Nat Genet. 2000;24(2):132–8.PubMedCrossRef
18.
Tsuchiya T, Sekine K, Hinohara S, Namiki T, Nobori T, Kaneko Y. Analysis of the p16INK4, p14ARF, p15, TP53, and MDM2 genes and their prognostic implications in osteosarcoma and Ewing sarcoma. Cancer Genet Cytogenet. 2000;120(2):91–8.PubMedCrossRef
19.
Hurtubise A, Bernstein ML, Momparler RL. Preclinical evaluation of the antineoplastic action of 5-aza-2'-deoxycytidine and different histone deacetylase inhibitors on human Ewing's sarcoma cells. Cancer Cell Int. 2008;8:16.PubMedCrossRef
20.
Nestheide S, Bridge JA, Barnes M, Frayer R, Sumegi J. Pharmacologic inhibition of epigenetic modification reveals targets of aberrant promoter methylation in Ewing Sarcoma. Pediatr Blood Cancer.
21.
Sievers S, Fritzsch C, Lehnhardt M, et al. Hypermethylation of the APC promoter but lack of APC mutations in myxoid/round-cell liposarcoma. Int J Cancer. 2006;119(10):2347–52.PubMedCrossRef
22.
23.
Freitas MA, Sklenar AR, Parthun MR. Application of mass spectrometry to the identification and quantification of histone post-translational modifications. J Cell Biochem. 2004;92(4):691–700.PubMedCrossRef
24.
Bannister AJ, Kouzarides T. Regulation of chromatin by histone modifications. Cell Res. 2011;21(3):381–95.PubMedCrossRef
25.
Gu W, Roeder RG. Activation of p53 sequence-specific DNA binding by acetylation of the p53 C-terminal domain. Cell. 1997;90(4):595–606.PubMedCrossRef
26.
Patel JH, Du Y, Ard PG, et al. The c-MYC oncoprotein is a substrate of the acetyltransferases hGCN5/PCAF and TIP60. Mol Cell Biol. 2004;24(24):10826–34.PubMedCrossRef
27.
Ververis K, Hiong A, Karagiannis TC, Licciardi PV. Histone deacetylase inhibitors (HDACIs): multitargeted anticancer agents. Biologics. 2013;7:47–60.PubMed
28.
Nakagawa M, Oda Y, Eguchi T, et al. Expression profile of class I histone deacetylases in human cancer tissues. Oncol Rep. 2007;18(4):769–74.PubMed
29.
Kutko MC, Glick RD, Butler LM, et al. Histone deacetylase inhibitors induce growth suppression and cell death in human rhabdomyosarcoma in vitro. Clin Cancer Res. 2003;9(15):5749–55.PubMed
30.
Maeda T, Nagaoka Y, Kawai Y, et al. Inhibitory effects of cancer cell proliferation by novel histone deacetylase inhibitors involve p21/WAF1 induction and G2/M arrest. Biol Pharm Bull. 2005;28(5):849–53.PubMedCrossRef
31.
Yamamoto S, Tanaka K, Sakimura R, et al. Suberoylanilide hydroxamic acid (SAHA) induces apoptosis or autophagy-associated cell death in chondrosarcoma cell lines. Anticancer Res. 2008;28(3A):1585–91.PubMed
32.
Muhlenberg T, Zhang Y, Wagner AJ, et al. Inhibitors of deacetylases suppress oncogenic KIT signaling, acetylate HSP90, and induce apoptosis in gastrointestinal stromal tumors. Cancer Res. 2009;69(17):6941–50.PubMedCrossRef
33.
Liu S, Cheng H, Kwan W, Lubieniecka JM, Nielsen TO. Histone deacetylase inhibitors induce growth arrest, apoptosis, and differentiation in clear cell sarcoma models. Mol Cancer Ther. 2008;7(6):1751–61.PubMedCrossRef
34.
Su L, Sampaio AV, Jones KB, et al. Deconstruction of the SS18-SSX fusion oncoprotein complex: insights into disease etiology and therapeutics. Cancer Cell 2012;21:333–47.
35.
Wittenburg LA, Bisson L, Rose BJ, Korch C, Thamm DH. The histone deacetylase inhibitor valproic acid sensitizes human and canine osteosarcoma to doxorubicin. Cancer Chemother Pharmacol;67(1):83-92.
36.
Yang C, Choy E, Hornicek FJ, et al. Histone deacetylase inhibitor PCI-24781 enhances chemotherapy-induced apoptosis in multidrug-resistant sarcoma cell lines. Anticancer Res 31(4):1115-23.
37.
Yang C, Choy E, Hornicek FJ, et al. Histone deacetylase inhibitor (HDACI) PCI-24781 potentiates cytotoxic effects of doxorubicin in bone sarcoma cells. Cancer Chemother Pharmacol;67(2):439-46.
38.
Edwin Choy SB, James Butrynski, Jeffrey Morgan, Mint Sirisawad, Chitra Mani, Suzanne George, Andrew Wagner, David Harmon, Yael Rubinstein, Zhenfeng Duan, Francis Hornicek, George Demetri. Massachusetts General Hospital, Boston, MA, . Phase I dose escalation study of abexinostat and doxorubicin in patients with metastatic sarcomas. In: American Association for Cancer Research Annual Meeting; 2013; Washington, D.C.; 2013.
39.
Mermoud JE, Rowbotham SP, Varga-Weisz PD. Keeping chromatin quiet: how nucleosome remodeling restores heterochromatin after replication. Cell Cycle. 2011;10(23):4017–25.PubMedCrossRef
40.
Jackson EM, Sievert AJ, Gai X, et al. Genomic analysis using high-density single nucleotide polymorphism-based oligonucleotide arrays and multiplex ligation-dependent probe amplification provides a comprehensive analysis of INI1/SMARCB1 in malignant rhabdoid tumors. Clin Cancer Res. 2009;15(6):1923–30.PubMedCrossRef
41.
Versteege I, Sevenet N, Lange J, et al. Truncating mutations of hSNF5/INI1 in aggressive paediatric cancer. Nature. 1998;394(6689):203–6.PubMedCrossRef
42.
Biegel JA, Zhou JY, Rorke LB, Stenstrom C, Wainwright LM, Fogelgren B. Germ-line and acquired mutations of INI1 in atypical teratoid and rhabdoid tumors. Cancer Res. 1999;59(1):74–9.PubMed
43.
Kohashi K, Oda Y, Yamamoto H, et al. SMARCB1/INI1 protein expression in round cell soft tissue sarcomas associated with chromosomal translocations involving EWS: a special reference to SMARCB1/INI1 negative variant extraskeletal myxoid chondrosarcoma. Am J Surg Pathol. 2008;32(8):1168–74.PubMedCrossRef
44.
Kohashi K, Izumi T, Oda Y, et al. Infrequent SMARCB1/INI1 gene alteration in epithelioid sarcoma: a useful tool in distinguishing epithelioid sarcoma from malignant rhabdoid tumor. Hum Pathol. 2009;40(3):349–55.PubMedCrossRef
45.
Mobley BC, McKenney JK, Bangs CD, et al. Loss of SMARCB1/INI1 expression in poorly differentiated chordomas. Acta Neuropathol. 2010;120(6):745–53.PubMedCrossRef
46.••
Kadoch C, Crabtree GR. Reversible Disruption of mSWI/SNF (BAF) Complexes by the SS18-SSX Oncogenic Fusion in Synovial Sarcoma. Cell. 2013;153(1):71–85. In this article by Kodoch and Crabtree they determine for the first time that the translocation product SS18-SSX in Synovial Sarcoma disrupts the function of SWI/SNF. They show evidence that this leads to transcription silencing and as such may drive oncogenesis. If these data hold true, it will be an important step in the search for novel therapies for this disease. PubMedCrossRef
47.
Kennison JA. The Polycomb and Trithorax group proteins of Drosophila: trans-regulators of homeotic gene function. Annu Rev Genet. 1995;29:289–303.PubMedCrossRef
48.
Shao Z, Raible F, Mollaaghababa R, et al. Stabilization of chromatin structure by PRC1, a Polycomb complex. Cell. 1999;98(1):37–46.PubMedCrossRef
49.
Simon JA, Lange CA. Roles of the EZH2 histone methyltransferase in cancer epigenetics. Mutat Res. 2008;647(1–2):21–9.PubMed
50.
Staege MS, Hutter C, Neumann I, et al. DNA microarrays reveal relationship of Ewing family tumors to both endothelial and fetal neural crest-derived cells and define novel targets. Cancer Res. 2004;64(22):8213–21.PubMedCrossRef
51.
Riggi N, Suva ML, Suva D, et al. EWS-FLI-1 expression triggers a Ewing's sarcoma initiation program in primary human mesenchymal stem cells. Cancer Res. 2008;68(7):2176–85.PubMedCrossRef
52.
Richter GH, Plehm S, Fasan A, et al. EZH2 is a mediator of EWS/FLI1 driven tumor growth and metastasis blocking endothelial and neuro-ectodermal differentiation. Proc Natl Acad Sci U S A. 2009;106(13):5324–9.PubMedCrossRef
53.
Burdach S, Plehm S, Unland R, et al. Epigenetic maintenance of stemness and malignancy in peripheral neuroectodermal tumors by EZH2. Cell Cycle 2009;8:1991–6.
54.
Changchien YC, Tatrai P, Papp G, et al. Poorly differentiated synovial sarcoma is associated with high expression of enhancer of zeste homologue 2 (EZH2). J Transl Med. 2012;10:216.PubMedCrossRef
55.
Fenaux P, Mufti GJ, Hellstrom-Lindberg E, et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol. 2009;10(3):223–32.PubMedCrossRef
56.
Kantarjian H, Issa JP, Rosenfeld CS, et al. Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study. Cancer. 2006;106(8):1794–803.PubMedCrossRef
57.
Straus DJ, Duvic M, Kuzel T, et al. Results of a phase II trial of oral bexarotene (Targretin) combined with interferon alfa-2b (Intron-A) for patients with cutaneous T-cell lymphoma. Cancer 2007;109:1799–803.
58.
Olsen EA, Kim YH, Kuzel TM, et al. Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma. J Clin Oncol. 2007;25(21):3109–15.PubMedCrossRef
59.
Piekarz RL, Frye R, Prince HM, et al. Phase 2 trial of romidepsin in patients with peripheral T-cell lymphoma. Blood. 2011;117(22):5827–34.PubMedCrossRef
60.
Ryan QC, Headlee D, Acharya M, et al. Phase I and pharmacokinetic study of MS-275, a histone deacetylase inhibitor, in patients with advanced and refractory solid tumors or lymphoma. J Clin Oncol. 2005;23(17):3912–22.PubMedCrossRef
61.
Schmitt T, Liu L, Leisen M, Ho AD, Burhenne J, Mikus G, Egerer G. Pharmacokinetic analyses of vorinostat in patients with metastatic soft tissue sarcoma. In: ASCO; 2012; Chicago; 2012.
62.
Schelman WR, Schell K, Marnocha R, Eickhoff J, Alberti D, Wilding G, Bailey H. A phase I study of vorinostat in combination with bortezomib in refractory solid tumors. In: ASCO Annual Meeting; 2007; 2007.
63.
Attia S, Okuno SH, Adkins D, Ahuja HG, Ducker TP, Maples WJ, Ochs L, Wentworth-Hartung NL, Erlichman C, Bailey HH. A phase II consortium trial of vorinostat and bortezomib for advanced soft tissue sarcomas. In: ASCO Annual Meeting; 2011; Chicago, IL; 2011.
64.
Banerji U, van Doorn L, Papadatos-Pastos D, et al. A phase I pharmacokinetic and pharmacodynamic study of CHR-3996, an oral class I selective histone deacetylase inhibitor in refractory solid tumors. Clin Cancer Res. 2012;18(9):2687–94.PubMedCrossRef
65.
Muscal JA, Thompson PA, Horton TM, et al. A phase I trial of vorinostat and bortezomib in children with refractory or recurrent solid tumors: a Children's Oncology Group phase I consortium study (ADVL0916). Pediatr Blood Cancer. 2013;60(3):390–5.
Metadata
Title
Role of Epigenetic Modulation for the Treatment of Sarcoma
Authors
Gregory M. Cote, MD, PhD
Edwin Choy, MD, PhD
Publication date
01-09-2013
Publisher
Springer US
Published in
Current Treatment Options in Oncology / Issue 3/2013
Print ISSN: 1527-2729
Electronic ISSN: 1534-6277
DOI
https://doi.org/10.1007/s11864-013-0239-3

Other articles of this Issue 3/2013

Current Treatment Options in Oncology 3/2013 Go to the issue

Sarcoma (SH Okuno, Section Editor)

The Role of Radiation in Retroperitoneal Sarcomas

Upper Gastrointestinal Cancers (JD Berlin, Section Editor)

Current Therapy and Future Directions in Biliary Tract Malignancies

Sarcoma (SH Okuno, Section Editor)

Adjuvant Therapy for High-Risk Soft Tissue Sarcoma in the Adult

Lower Gastrointestinal Cancers (AB Benson, Section Editor)

Health Care Disparities in the Treatment of Colorectal Cancer

Sarcoma (SH Okuno, Section Editor)

Multidisciplinary Management of Recurrent Chordomas

Lower Gastrointestinal Cancers (AB Benson, Section Editor)

Evolving Treatment Strategies for Management of Carcinoid Tumors
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits